Literature DB >> 33591380

Advanced prostate cancer.

Marie C Hupe1, Axel S Merseburger2.   

Abstract

Entities:  

Year:  2021        PMID： 33591380     DOI： 10.1007/s00345-021-03618-4

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  7 in total

1.  Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial.

Authors:  Renée Bultijnck; Benedicte Deforche; Noëmi Borrey; Jörgen Van Bauwel; Maarten Lievens; Elke Rammant; Valérie Fonteyne; Karel Decaestecker; Adelheid Steyaert; Nicolaas Lumen; Piet Ost
Journal:  World J Urol       Date:  2020-02-01       Impact factor: 4.226

Review 2.  M0CRPC overview of management options.

Authors:  Y Hess-Busch; B Hadaschik; J Hess
Journal:  World J Urol       Date:  2019-11-05       Impact factor: 4.226

3.  A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer.

Authors:  A Holmes; B D Kelly; M Perera; R S Eapen; D M Bolton; N Lawrentschuk
Journal:  World J Urol       Date:  2020-06-04       Impact factor: 4.226

4.  Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries.

Authors:  Aurélie De Bruycker; Phuoc T Tran; Ariel H Achtman; Piet Ost
Journal:  World J Urol       Date:  2020-01-18       Impact factor: 4.226

Review 5.  Navigating systemic therapy for metastatic castration-naïve prostate cancer.

Authors:  E M Kwan; I A Thangasamy; J Teh; O Alghazo; N J Sathianathen; N Lawrentschuk; A A Azad
Journal:  World J Urol       Date:  2020-01-02       Impact factor: 4.226

6.  Essential elements of anaesthesia practice in ERAS programs.

Authors:  Géraldine Pignot; Clément Brun; Maxime Tourret; François Lannes; Sami Fakhfakh; Stanislas Rybikowski; Thomas Maubon; Marion Picini; Jochen Walz
Journal:  World J Urol       Date:  2020-08-25       Impact factor: 3.661

7.  Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice.

Authors:  Patrick Davey; Mike G Kirby
Journal:  World J Urol       Date:  2020-09-26       Impact factor: 3.661
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.